Evaluating the Utility of PDE10 Inhibition in Huntington’s Disease

Beaumont et al. demonstrate that acute PDE10 inhibition boosts diminished corticostriatal input and indirect pathway output in symptomatic HD models, despite loss of PDE10. Their data provide rationale for a PDE10i clinical trial to assess symptom improvement in HD patients.